Seminars in Radiation Oncology
Volume 20, Issue 2 , Pages 138-146 , April 2010

Adapting Biological Feedback in Radiotherapy

  • Åste Søvik, PhD, DVM

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    • Department of Companion Animal Clinical Sciences, Norwegian School of Veterinary Science, Oslo, Norway
    • Corresponding Author InformationAddress reprint requests to Åste Søvik, PhD, DVM, Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway
    • ,
  • Eirik Malinen, PhD

      Affiliations

    • Department of Medical Physics, Division of Cancer Medicine and Radiotherapy, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    • ,
  • Dag Rune Olsen, PhD

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    • Department of Physics, University of Oslo, Oslo, Norway

References 

  1. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004;14:198–206
  2. Munley MT, Marks LB, Hardenbergh PH. Functional imaging of normal tissues with nuclear medicine: Applications in radiotherapy. Semin Radiat Oncol. 2001;11:28–36
  3. Ling CC, Humm J, Larson S. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–560
  4. Bentzen SM. Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol. 2005;6:112–117
  5. Sovik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: A review. Int J Radiat Oncol Biol Phys. 2009;73:650–658
  6. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 2002;54:921–927
  7. Søvik Å, Malinen E, Bruland OS. Optimization of tumor control probability in hypoxic tumors by radiation dose redistribution: A modelling study. Phys Med Biol. 2007;52:499–513
  8. Das SK, Miften MM, Zhou S. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys. 2004;31:1452–1461
  9. van Lin EN, Futterer JJ, Heijmink SW. IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65:291–303
  10. Vanderstraeten B, Duthoy W, Gersem WD. [18F]fluoro-deoxy-glucose positron emission tomography ([(18)F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol. 2006;79:249–258
  11. Thorwarth D, Eschmann SM, Paulsen F. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys. 2007;68:291–300
  12. Chen GP, Ahunbay E, Schultz C. Development of an inverse optimization package to plan nonuniform dose distributions based on spatially inhomogeneous radiosensitivity extracted from biological images. Med Phys. 2007;34:1198–1205
  13. Lee NY, Mechalakos JG, Nehmeh S. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2–13
  14. Madani I, Duthoy W, Derie C. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68:126–135
  15. Zhang G, Dilling TJ, Stevens CW. Functional lung imaging in thoracic cancer radiotherapy. Cancer Control. 2008;15:112–119
  16. Seppenwoolde Y, Engelsman M, De JK. Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol. 2002;63:165–177
  17. McGuire SM, Zhou S, Marks LB. A methodology for using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung. Int J Radiat Oncol Biol Phys. 2006;66:1543–1552
  18. Lavrenkov K, Singh S, Christian JA. Effective avoidance of a functional spect-perfused lung using intensity modulated radiotherapy (IMRT) for non-small cell lung cancer (NSCLC): An update of a planning study. Radiother Oncol. 2009;91:349–352
  19. Christian JA, Partridge M, Nioutsikou E. The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer. Radiother Oncol. 2005;77:271–277
  20. Sovik A, Malinen E, Skogmo HK. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys. 2007;68:1496–1504
  21. Gray LH, Conger AD, Ebert M. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638–648
  22. Chao KS, Bosch WR, Mutic S. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171–1182
  23. Alber M, Paulsen F, Eschmann SM. On biologically conformal boost dose optimization. Phys Med Biol. 2003;48:N31–N35
  24. Grosu AL, Souvatzoglou M, Roper B. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:541–551
  25. Vaupel P, Harrison L. Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9(suppl 5):4–9
  26. Brurberg KG, Skogmo HK, Graff BA. Fluctuations in pO2 in poorly and well-oxygenated spontaneous canine tumors before and during fractionated radiation therapy. Radiother Oncol. 2005;77:220–226
  27. Kallman RF, Dorie MJ. Tumor oxygenation and reoxygenation during radiation therapy: Their importance in predicting tumor response. Int J Radiat Oncol Biol Phys. 1986;12:681–685
  28. Eschmann SM, Paulsen F, Bedeshem C. Hypoxia-imaging with (18)F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83:406–410
  29. Abramyuk A, Tokalov S, Zophel K. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?. Radiother Oncol. 2009;91:399–404
  30. Soto DE, Kessler ML, Piert M. Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol. 2008;89:13–18
  31. Aerts HJ, van Baardwijk AA, Petit SF. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol. 2009;91:386–392
  32. Solberg TD, Agazaryan N, Goss BW. A feasibility study of 18F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy. J Neurosurg. 2004;101(suppl 3):381–389
  33. Narayana A, Chang J, Thakur S. Use of MR spectroscopy and functional imaging in the treatment planning of gliomas. Br J Radiol. 2007;80:347–354
  34. Brahme A. Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncol. 2003;42:123–136
  35. Kong FM, Frey KA, Quint LE. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol. 2007;25:3116–3123
  36. van Baardwijk A, Bosmans G, Dekker A. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy (A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients). Radiother Oncol. 2007;82:145–152
  37. Brun E, Kjellen E, Tennvall J. FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127–135
  38. Wieder HA, Brucher BL, Zimmermann F. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900–908
  39. Evans ES, Hahn CA, Kocak Z. The role of functional imaging in the diagnosis and management of late normal tissue injury. Semin Radiat Oncol. 2007;17:72–80
  40. Ruysscher DD, Houben A, Aerts HJ. Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): A prospective pilot study. Radiother Oncol. 2009;91:415–420
  41. Garcia-Alvarez R, Liney GP, Beavis AW. Use of functional magnetic resonance imaging in the treatment planning of intensity modulated radiotherapy. J Radiother Pract. 2003;3:55–62
  42. Shioyama Y, Jang SY, Liu HH. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;68:1349–1358
  43. Seppenwoolde Y, Muller SH, Theuws JC. Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;47:681–690
  44. Allal AS, Slosman DO, Kebdani T. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295–1300
  45. Thorwarth D, Eschmann SM, Holzner F. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol. 2006;80:151–156
  46. Zahra MA, Hollingsworth KG, Sala E. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol. 2007;8:63–74
  47. Beck R, Roper B, Carlsen JM. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973–980
  48. Zakian KL, Sircar K, Hricak H. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804–814
  49. Pirzkall A, McKnight TR, Graves EE. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys. 2001;50:915–928
  50. Dehdashti F, Grigsby PW, Mintun MA. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response—a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233–1238
  51. Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue. J Nucl Med. 1993;34:419–421
  52. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004;4:891–899
  53. Chen W, Cloughesy T, Kamdar N. Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med. 2005;46:945–952
  54. Buck AK, Halter G, Schirrmeister H. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44:1426–1431
  55. Krause BJ, Beck R, Souvatzoglou M. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging. 2006;50:28–43
  56. Apisarnthanarax S, Chao KS. Current imaging paradigms in radiation oncology. Radiat Res. 2005;163:1–25
  57. Souvatzoglou M, Grosu AL, Roper B. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: A pilot study. Eur J Nucl Med Mol Imaging. 2007;34:1566–1575
  58. Thorwarth D, Eschmann SM, Paulsen F. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys. 2007;68:515–521
  59. Agarwal R, Brunelli SM, Williams K. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: A systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24:856–863
  60. Kaus MR, Brock KK, Pekar V. Assessment of a model-based deformable image registration approach for radiation therapy planning. Int J Radiat Oncol Biol Phys. 2007;68:572–580
  61. Castadot P, Lee JA, Parraga A. Comparison of 12 deformable registration strategies in adaptive radiation therapy for the treatment of head and neck tumors. Radiother Oncol. 2008;89:1–12
  62. Mankoff DA, Muzi M, Krohn KA. Quantitative positron emission tomography imaging to measure tumor response to therapy: What is the best method?. Mol Imaging Biol. 2003;5:281–285
  63. Weber WA. PET for response assessment in oncology: Radiotherapy and chemotherapy. Br J Radiol. 2005;S28:42–47
  64. South CP, Partridge M, Evans PM. A theoretical framework for prescribing radiotherapy dose distributions using patient-specific biological information. Med Phys. 2008;35:4599–4611
  65. Marks LB, Spencer DP, Sherouse GW. The role of three dimensional functional lung imaging in radiation treatment planning: The functional dose-volume histogram. Int J Radiat Oncol Biol Phys. 1995;33:65–75
  66. Yang Y, Xing L. Towards biologically conformal radiation therapy (BCRT): Selective IMRT dose escalation under the guidance of spatial biology distribution. Med Phys. 2005;32:1473–1484
  67. Gillham C, Zips D, Ponisch F. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiother Oncol. 2008;88:335–341

 This work was supported by the Norwegian Cancer Society.

PII: S1053-4296(09)00082-4

doi: 10.1016/j.semradonc.2009.11.008

Seminars in Radiation Oncology
Volume 20, Issue 2 , Pages 138-146 , April 2010

Article Tools

* Image Usage & Resolution